Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
Venetoclax is efficacious in relapsed/refractory t(11;14) multiple myeloma, thus warranting investigation in light-chain amyloidosis (AL). This retrospective cohort includes 43 patients with previously treated AL, from 14 centers in the US and Europe. Thirty-one patients harbored t(11;14), 11 did no...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 January 2021
|
| In: |
Blood cancer journal
Year: 2021, Jahrgang: 11, Heft: 1, Pages: 1-10 |
| ISSN: | 2044-5385 |
| DOI: | 10.1038/s41408-020-00397-w |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41408-020-00397-w Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41408-020-00397-w 
|
| Verfasserangaben: | Vikram J. Premkumar, Suzanne Lentzsch, Samuel Pan, Divaya Bhutani, Joshua Richter, Sundar Jagannath, Michaela Liedtke, Arnaud Jaccard, Ashutosh D. Wechalekar, Raymond Comenzo, Vaishali Sanchorawala, Bruno Royer, Michael Rosenzweig, Jason Valent, Stefan Schönland, Rafael Fonseca, Sandy Wong and Prashant Kapoor |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1750875829 | ||
| 003 | DE-627 | ||
| 005 | 20230426083824.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210309s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41408-020-00397-w |2 doi | |
| 035 | |a (DE-627)1750875829 | ||
| 035 | |a (DE-599)KXP1750875829 | ||
| 035 | |a (OCoLC)1341398191 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Premkumar, Vikram |e VerfasserIn |0 (DE-588)1228953120 |0 (DE-627)1750875853 |4 aut | |
| 245 | 1 | 0 | |a Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis |c Vikram J. Premkumar, Suzanne Lentzsch, Samuel Pan, Divaya Bhutani, Joshua Richter, Sundar Jagannath, Michaela Liedtke, Arnaud Jaccard, Ashutosh D. Wechalekar, Raymond Comenzo, Vaishali Sanchorawala, Bruno Royer, Michael Rosenzweig, Jason Valent, Stefan Schönland, Rafael Fonseca, Sandy Wong and Prashant Kapoor |
| 264 | 1 | |c 11 January 2021 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.03.2021 | ||
| 520 | |a Venetoclax is efficacious in relapsed/refractory t(11;14) multiple myeloma, thus warranting investigation in light-chain amyloidosis (AL). This retrospective cohort includes 43 patients with previously treated AL, from 14 centers in the US and Europe. Thirty-one patients harbored t(11;14), 11 did not, and one t(11;14) status was unknown. Patients received a venetoclax-containing regimen for at least one 21- or 28-day cycle; the median prior treatments was three. The hematologic response rate for all patients was 68%; 63% achieved VGPR/CR. t(11;14) patients had higher hematologic response (81% vs. 40%) and higher VGPR/CR rate (78% vs. 30%, odds ratio: 0.12, 95% CI 0.02-0.62) than non-t(11;14) patients. For the unsegregated cohort, median progression-free survival (PFS) was 31.0 months and median OS was not reached (NR). For t(11;14), median PFS was NR and for non-t(11;14) median PFS was 6.7 months (HR: 0.14, 95% CI 0.04-0.53). Multivariate analysis incorporating age, sex, prior lines of therapy, and disease stage suggested a risk reduction for progression or death in t(11;14) patients. Median OS was NR for either subgroup. The organ response rate was 38%; most responders harbored t(11;14). Grade 3 or higher adverse events occurred in 19% with 7% due to infections. These promising results require confirmation in a randomized clinical trial. | ||
| 700 | 1 | |a Lentzsch, Suzanne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pan, Samuel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bhutani, Divaya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Richter, Joshua |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jagannath, Sundar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Liedtke, Michaela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jaccard, Arnaud |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wechalekar, Ashutosh D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Comenzo, Raymond |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sanchorawala, Vaishali |e VerfasserIn |4 aut | |
| 700 | 1 | |a Royer, Bruno |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rosenzweig, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Valent, Jason |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schönland, Stefan |d 1969- |e VerfasserIn |0 (DE-588)122405226 |0 (DE-627)705896137 |0 (DE-576)293255792 |4 aut | |
| 700 | 1 | |a Fonseca, Rafael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wong, Sandy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kapoor, Prashant |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood cancer journal |d [London] : Springer Nature, 2011 |g 11(2021), 1, Artikel-ID 10, Seite 1-10 |h Online-Ressource |w (DE-627)655134174 |w (DE-600)2600560-8 |w (DE-576)339571802 |x 2044-5385 |7 nnas |a Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:1 |g elocationid:10 |g pages:1-10 |g extent:10 |a Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41408-020-00397-w |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/s41408-020-00397-w |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210309 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 122405226 |a Schönland, Stefan |m 122405226:Schönland, Stefan |d 910000 |d 910100 |d 50000 |e 910000PS122405226 |e 910100PS122405226 |e 50000PS122405226 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 15 | ||
| 999 | |a KXP-PPN1750875829 |e 3883433918 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Vikram","role":"aut","display":"Premkumar, Vikram","family":"Premkumar"},{"role":"aut","given":"Suzanne","display":"Lentzsch, Suzanne","family":"Lentzsch"},{"role":"aut","given":"Samuel","display":"Pan, Samuel","family":"Pan"},{"given":"Divaya","role":"aut","display":"Bhutani, Divaya","family":"Bhutani"},{"given":"Joshua","role":"aut","display":"Richter, Joshua","family":"Richter"},{"role":"aut","given":"Sundar","family":"Jagannath","display":"Jagannath, Sundar"},{"family":"Liedtke","display":"Liedtke, Michaela","role":"aut","given":"Michaela"},{"role":"aut","given":"Arnaud","family":"Jaccard","display":"Jaccard, Arnaud"},{"given":"Ashutosh D.","role":"aut","display":"Wechalekar, Ashutosh D.","family":"Wechalekar"},{"given":"Raymond","role":"aut","display":"Comenzo, Raymond","family":"Comenzo"},{"given":"Vaishali","role":"aut","display":"Sanchorawala, Vaishali","family":"Sanchorawala"},{"role":"aut","given":"Bruno","display":"Royer, Bruno","family":"Royer"},{"family":"Rosenzweig","display":"Rosenzweig, Michael","given":"Michael","role":"aut"},{"role":"aut","given":"Jason","family":"Valent","display":"Valent, Jason"},{"given":"Stefan","role":"aut","family":"Schönland","display":"Schönland, Stefan"},{"given":"Rafael","role":"aut","family":"Fonseca","display":"Fonseca, Rafael"},{"role":"aut","given":"Sandy","family":"Wong","display":"Wong, Sandy"},{"family":"Kapoor","display":"Kapoor, Prashant","given":"Prashant","role":"aut"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"11 January 2021","dateIssuedKey":"2021"}],"note":["Gesehen am 09.03.2021"],"title":[{"title_sort":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis","title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis"}],"id":{"eki":["1750875829"],"doi":["10.1038/s41408-020-00397-w"]},"name":{"displayForm":["Vikram J. Premkumar, Suzanne Lentzsch, Samuel Pan, Divaya Bhutani, Joshua Richter, Sundar Jagannath, Michaela Liedtke, Arnaud Jaccard, Ashutosh D. Wechalekar, Raymond Comenzo, Vaishali Sanchorawala, Bruno Royer, Michael Rosenzweig, Jason Valent, Stefan Schönland, Rafael Fonseca, Sandy Wong and Prashant Kapoor"]},"physDesc":[{"extent":"10 S."}],"relHost":[{"language":["eng"],"part":{"text":"11(2021), 1, Artikel-ID 10, Seite 1-10","issue":"1","year":"2021","pages":"1-10","volume":"11","extent":"10"},"recId":"655134174","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2600560-8"],"issn":["2044-5385"],"eki":["655134174"]},"title":[{"title_sort":"Blood cancer journal","title":"Blood cancer journal"}],"origin":[{"dateIssuedKey":"2017","publisher":"Springer Nature ; Nature Publ. Group","dateIssuedDisp":"2017-","publisherPlace":"[London] ; London [u.a.]"}],"pubHistory":["1.2011-"],"note":["Gesehen am 17.07.24"],"disp":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosisBlood cancer journal","type":{"media":"Online-Ressource","bibl":"periodical"}}],"recId":"1750875829"} | ||
| SRT | |a PREMKUMARVVENETOCLAX1120 | ||